Back to Health A to Z. Herceptin is the brand name of a medicine called trastuzumab. Herceptin can help control the growth of cancer cells that contain high amounts of human epidermal growth factor receptor 2 HER2. High levels of HER2 are found in some types of breast, oesophageal and stomach cancer, which helps the cancer cells grow and survive.
Herceptin for breast cancer
Herceptin for breast cancer | CANCERactive
The research suggests that treating patients with chemotherapy, Herceptin, and one of two common cardiac drugs reduces heart damage. Breast cancer patients who take either of two heart medicines while undergoing treatment with Herceptin trastuzumab were not protected from the cardiac damage that is a common side effect of Herceptin therapy. But the patients did benefit from either of the two common heart drugs if they had already undergone treatment with drugs called anthracyclines before starting Herceptin, or if they were being treated with anthracyclines and Herceptin at the same time. Anthracyclines, such as Adriamycin or Rubex doxorubicin , are chemotherapy drugs. Both anthracyclines and Herceptin are significant medicines for managing a common type of breast cancer called HER2-positive breast cancer. The study is one the first and the largest to explore whether cardiac medication can prevent heart damage linked to Herceptin.
Access to breast cancer drugs: what to look out for in 2021
Background: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 HER2 , progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. Methods: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported.
We share an update on which breast cancer drugs may be assessed for use on the NHS this year, and recap which drugs were approved for use in Drugs are a cornerstone of breast cancer treatment, which is why our work on access to drugs is so crucial. We participate in every assessment of a new breast cancer drug, always ensuring the patient voice is heard by decision-makers. We're grateful to everyone who has shared their experiences with us. Atezolizumab is a type of immunotherapy given in combination with chemotherapy drug nab-paclitaxel.